NLRP3-inhibitors have been developed and tested in MASH models since cell death and pyroptosis play crucial roles in the progression from benign MASLD to inflammatory MASH. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.